Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

ELVN

Phase 1a

ELVN-001

Chronic Myeloid Leukemia (CML)

2025

9/28/24 Updated positive Ph1a data at ESH-iCMLf conference. Additional Ph1 data in 2025.

Additional data readout

AUTL

Phase 1

AUTO6NG

Neuroblastoma and other tumors

2025

MAGNETO: Collaboration with UCL, Initiation in Q4 2023. Data update in 2025.

Data readout

CALC

Phase 2

Auxora™

Acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF)

2025

KOURAGE trial. 7/9/24- First patient enrolled with topline data in 2025.

Data readout

ALVO

PDUFA

AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Eye disorders

Q4 2025

Collab with TEVA. 2/18/25- BLA accepted. Regulatory approval in Q4 2025.

Approval decision

SAGE

Phase 1

SAGE-319

Behavioral symptoms associated with certain neurodevelopmental disorders

late 2025

Data from a Ph1 multiple ascending dose (MAD) study by late 2025.

Data readout

SLDB

Phase 1b

SGT-212 (dual route)

Friedreich’s Ataxia

H2 2025

1/21/25- FDA Fast Track Designation. Planned Ph1b trial. Initiate dosing in H2 2025.

Initiation

ALKS

Phase 2

ALKS 2680 (RDC-264177) ( Orexin 2 Receptor Agonist)

Narcolepsy type 2 (NT2)

H2 2025

Vibrance-2 study (NT2). Q3'24- Ph2 initiated in August 2024. Positive Ph1b data presented at Sleep Europe 2024 in September. Complete ongoing Ph2 study in 2025, with potential for registrational studies preparation. 2/12/25- Data expected in H2 2025.

Data readout

MOR

Phase 3

Tafasitamab (CD19)

First-line Diffuse large B cell lymphoma (DLBCL)

H2 2025

frontMind study. Tafasitamab plus lenalidomide in addition to rituximab. Enrollment complete 4/4/23. Topline data in H2 2025. 2/5/24 Asset purchase w/ Incyte.

Data readout

SLS

Phase 3

Galinpepimut-S

AML (Acute Myeloid Leukemia)

2025

REGAL study. 3/26/24- Enrollment complete. 10/15/24- RPDD granted. 12/10/24- Pre-specified death threshold reached. 1/23/25- Reported outcome of interim analysis. IDMC recommended continuation of trial. Next & final analysis planned upon reaching 80 events in 2025.

Data readout

NGNE

Phase 1/2

NGN-401

Rett syndrome

H2 2025

11/11/24- Reported interim data from first four low-dose pedia participants. 11/18/24- Update on registrational trial design in H1 2025. Announce additional interim Ph1/2 data in H2 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20